Treat Update. 1998 Dec;10(10):2. Unique Identifier : AIDSLINE
Researchers at Trimeris Inc. have developed and tested a small molecule,
called T-20, which prevents HIV from attaching to cells. Preliminary
results show a dramatic decline in HIV levels, and the drug appears to
have low toxicity. T-20 is given via infusion, although other companies
are developing similar compounds that can be taken through the nose.
Study details and results are briefly described. Some concerns regarding
T-20 include long term toxicity and its interaction with other drugs.
NEWSLETTER ARTICLE Anti-HIV Agents/*PHARMACOLOGY Dose-Response
Relationship, Drug Drugs, Investigational HIV Envelope Protein
gp41/*PHARMACOLOGY HIV Infections/*DRUG THERAPY/VIROLOGY HIV-1/DRUG
EFFECTS/PHYSIOLOGY Human Infusions, Intravenous Male Peptide
Fragments/PHARMACOLOGY Viral Load Virus Replication/*DRUG EFFECTS